Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Dosage form suitability in vulnerable populations: A focus on paracetamol acceptability from infants to centenarians.

Ruiz F, Vallet T, Dufaÿ Wojcicki A, Belissa É, Fontan JE, de Pontual L, Nathanson S, Chevallier A, Laribe-Caget S, Boudy V.

PLoS One. 2019 Aug 20;14(8):e0221261. doi: 10.1371/journal.pone.0221261. eCollection 2019.

2.

Sex Differences in Medicine Acceptability: A New Factor to Be Considered in Medicine Formulation.

Ruiz F, Keeley A, Léglise P, Tuleu C, Lachuer C, Rwabihama JP, Bachalat N, Boulaich I, Abdallah F, Rabus M, Ribemont AC, Michelon H, Wojcicki AD, Orlu M, Vallet T, Boudy V.

Pharmaceutics. 2019 Aug 1;11(8). pii: E368. doi: 10.3390/pharmaceutics11080368.

3.

Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by Aedes Mosquitoes.

Delang L, Yen PS, Vallet T, Vazeille M, Vignuzzi M, Failloux AB.

mSphere. 2018 Aug 22;3(4). pii: e00230-18. doi: 10.1128/mSphere.00230-18.

4.

Complete Genome Sequence of a Novel Recombinant Citrus Tristeza Virus, a Resistance-Breaking Isolate from Uruguay.

Benítez-Galeano MJ, Vallet T, Carrau L, Hernández-Rodríguez L, Bertalmío A, Rivas F, Rubio L, Maeso D, Vignuzzi M, Moratorio G, Colina R.

Genome Announc. 2018 May 31;6(22). pii: e00442-18. doi: 10.1128/genomeA.00442-18.

5.

A Decision Support Tool Facilitating Medicine Design for Optimal Acceptability in The Older Population.

Vallet T, Belissa E, Laribe-Caget S, Chevallier A, Chedhomme FX, Leglise P, Piccoli M, Michelon H, Bloch V, Meaume S, Grancher AS, Bachalat N, Boulaich I, Abdallah F, Rabus M, Rwabihama JP, Ribemont AC, Lachuer C, Perquy I, Lechowski L, Delahaye A, Depoisson M, Orven Y, Guinot C, Gibaud S, Michel C, Mahiou A, Belbachir SA, Trouvin JH, Dufaÿ-Wojcicki A, Boudy V, Ruiz F.

Pharm Res. 2018 May 7;35(7):136. doi: 10.1007/s11095-018-2424-3.

6.

Dicer-2-Dependent Generation of Viral DNA from Defective Genomes of RNA Viruses Modulates Antiviral Immunity in Insects.

Poirier EZ, Goic B, Tomé-Poderti L, Frangeul L, Boussier J, Gausson V, Blanc H, Vallet T, Loyd H, Levi LI, Lanciano S, Baron C, Merkling SH, Lambrechts L, Mirouze M, Carpenter S, Vignuzzi M, Saleh MC.

Cell Host Microbe. 2018 Mar 14;23(3):353-365.e8. doi: 10.1016/j.chom.2018.02.001. Epub 2018 Mar 1.

7.

Standardised evaluation of medicine acceptability in paediatric population: reliability of a model.

Vallet T, Ruiz F, Lavarde M, Pensé-Lhéritier AM, Aoussat A.

J Pharm Pharmacol. 2018 Jan;70(1):42-50. doi: 10.1111/jphp.12829. Epub 2017 Oct 26.

8.

Attenuation of RNA viruses by redirecting their evolution in sequence space.

Moratorio G, Henningsson R, Barbezange C, Carrau L, Bordería AV, Blanc H, Beaucourt S, Poirier EZ, Vallet T, Boussier J, Mounce BC, Fontes M, Vignuzzi M.

Nat Microbiol. 2017 Jun 5;2:17088. doi: 10.1038/nmicrobiol.2017.88.

PMID:
28581455
9.

Chikungunya Virus Overcomes Polyamine Depletion by Mutation of nsP1 and the Opal Stop Codon To Confer Enhanced Replication and Fitness.

Mounce BC, Cesaro T, Vlajnić L, Vidiņa A, Vallet T, Weger-Lucarelli J, Passoni G, Stapleford KA, Levraud JP, Vignuzzi M.

J Virol. 2017 Jul 12;91(15). pii: e00344-17. doi: 10.1128/JVI.00344-17. Print 2017 Aug 1.

10.

Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding.

Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M.

Antiviral Res. 2017 Jun;142:148-157. doi: 10.1016/j.antiviral.2017.03.014. Epub 2017 Mar 24.

11.

Standardized method to assess medicines' acceptability: focus on paediatric population.

Ruiz F, Vallet T, Pensé-Lhéritier AM, Aoussat A.

J Pharm Pharmacol. 2017 Apr;69(4):406-416. doi: 10.1111/jphp.12547. Epub 2016 Apr 25.

12.

Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.

Vila J, Nugier F, Barguès G, Vallet T, Peyramond D, Hamedi-Sangsari F, Seigneurin JM.

Lancet. 1997 Aug 30;350(9078):635-6. No abstract available.

PMID:
9288048
13.

1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection.

Vila J, Biron F, Nugier F, Vallet T, Peyramond D.

Lancet. 1996 Jul 20;348(9021):203-4. No abstract available.

PMID:
8684186
14.

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.

Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, Vila J.

Antiviral Res. 1996 Jan;29(1):111-3. No abstract available.

PMID:
8721560
15.

Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.

Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, Vila J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):36-40.

PMID:
7648282
16.

Expression of the alpha 6, beta 1 and beta 4 integrin subunits, basement membrane organization and proteolytic capacities in low and high metastatic human colon carcinoma xenografts.

Daémi N, Vallet T, Thomasset N, Jacquier MF, Zebda N, Doré JF, Sordat B, Rémy L.

Invasion Metastasis. 1995;15(3-4):103-15.

PMID:
8621266

Supplemental Content

Loading ...
Support Center